Apr 10, 2025 8:00am EDT Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
Apr 01, 2025 7:00am EDT Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31, 2025 7:00am EDT Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Mar 13, 2025 7:00am EDT Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
Feb 20, 2025 7:00am EST Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Jan 28, 2025 7:00am EST Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Jan 07, 2025 7:00am EST Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Dec 17, 2024 7:00am EST Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
Nov 21, 2024 7:00am EST Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Nov 13, 2024 7:15am EST Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
